[{"id":"05f040e1-426f-4c8d-aae4-90d190a2911b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04163302","created_at":"2021-01-18T20:18:10.663Z","updated_at":"2024-07-02T16:36:53.664Z","phase":"Phase 2","brief_title":"Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma","source_id_and_acronym":"NCT04163302","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":" | ","alterations":" CD19 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19-PD1-CART cell"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2019","start_date":" 07/07/2019","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-11-15"}]